Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Major clinical study confirms efficacy and safety of rivastigmine in AD

March 17, 1999

NeoTherapeutics begins Neotrofin clinical trials in Canada and Australia

March 16, 1999

New salt of paroxetine with improved physicochemical characteristics

March 16, 1999

Biovail's Brexidol receives Canadian marketing approval

March 16, 1999

Novel sublingual apomorphine: efficacy and tolerability in fluctuating Parkinson's disease

March 16, 1999

Effexor XR receives FDA approval for treatment of GAD

March 15, 1999

GABA-A receptor ligands from MS&D for Alzheimer's disease

March 15, 1999

N-type calcium channel inhibitors described by Ono

March 15, 1999

Orally active analgesic agents in development at Otsuka

March 15, 1999

GABA-A alpha5 subunit-selective inverse agonists from Merck useful for Alzheimer's disease

March 12, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...